Behaviour, functional capacity and overall health status all decline with the increasing severity of Alzheimer's disease

Author： Yeardley H.L.   Berdeaux G.   Souecirc tre E.   Thwaites R.M.A.  

Publisher： Elsevier

ISSN： 0924-977X

Source： European Neuropsychopharmacology, Vol.5, Iss.3, 1995-09, pp. : 385-385

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Therapeutic Opportunities in Alzheimer Disease: One for all or all for One?

By  

Current Medicinal Chemistry, Vol. 12, Iss. 10, 2005-05 ,pp. : 1137-1147

Bentham Science Publishers

Access to resources Recommend Favorite

Rivastigmine on its best behaviour in Alzheimer's disease

By  

Inpharma, Vol. 1, Iss. 1239, 2000-01 ,pp. : 15-15

Adis International

Access to resources Recommend Favorite

Dietary Approaches and Supplements in the Prevention of Cognitive Decline and Alzheimer’s Disease

By  

Current Pharmaceutical Design, Vol. 22, Iss. 6, 2016-02 ,pp. : 688-700

Bentham Science Publishers

Access to resources Recommend Favorite

Commentary Research Highlights (Amyloid &bgr;-Peptide and Alzheimer's Disease: It's All the RAGE)

By  

CNS & Neurological Disorders - Drug Targets (Formerly Current Drug Targets - CNS & Neurological Disorders), Vol. 11, Iss. 5, 2012-08 ,pp. : 494-494

Bentham Science Publishers

Access to resources Recommend Favorite

Galantamine in the Treatment of Cognitive Decline in Patients with Vascular Dementia or Alzheimer’s Disease with Cerebrovascular Disease

By Small G.  

CNS Drugs, Vol. 17, Iss. 12, 2003-01 ,pp. : 905-914

Adis International

Access to resources Recommend Favorite